Favourable Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Metastatic Rectal Neuroendocrine Neoplasia (NEN)
Introduction: Metastatic disease from rectal NEN are less common than other NEN origins, and carries a poor prognosis. Treatment evidence for such patients (pts) is lacking.
Aim(s): We assessed PRRT outcomes in pts with somatostatin receptor (SSTR) positive metastatic rectal NEN from 2 referral centres.
Materials and methods: Pts treated with PRRT were retrospectively reviewed. Anatomical imaging (RECIST 1.1), SSTR imaging response and toxicity were assessed 3 months post-PRRT. Kaplan-Meier estimate was used to determine progression free survival (PFS) and overall survival (OS) from start of PRRT.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Kong G
To read the full abstract, please log into your ENETS Member account.